We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.97B
AUM Growth
-$356M
Cap. Flow
+$116M
Cap. Flow %
2.92%
Top 10 Hldgs %
30.63%
Holding
140
New
5
Increased
76
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$22.5M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$21.2M
3
DXCM icon
DexCom
DXCM
+$20.7M
4
IDXX icon
Idexx Laboratories
IDXX
+$20.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18M
3
IMRX icon
Immuneering
IMRX
+$17.6M
4
WHWK
Whitehawk Therapeutics
WHWK
+$13M
5
VERV
Verve Therapeutics
VERV
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.08%
2 Consumer Staples 1.53%
3 Industrials 0.67%
4 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
101
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.13M 0.13%
1,726,637
+29,532
+2% +$111K
THRX
102
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$5.04M 0.13%
437,329
– –
INZY
103
DELISTED
Inozyme Pharma
INZY
$4.88M 0.12%
1,193,195
+324,729
+37% +$1.91M
ADAP
104
DELISTED
Adaptimmune Therapeutics
ADAP
$4.73M 0.12%
2,297,194
+81,606
+4% +$220K
FATE icon
105
Fate Therapeutics
FATE
$322M
$4.26M 0.11%
110,000
– –
SYRE icon
106
Spyre Therapeutics
SYRE
$9.29B
$4.17M 0.1%
72,457
+9,365
+15% +$786K
CGEN icon
107
Compugen
CGEN
$221M
$4.15M 0.1%
1,289,990
– –
EQRX
108
DELISTED
EQRx, Inc. Common Stock
EQRX
$4.13M 0.1%
+1,000,000
New +$4.35M
KNTE
109
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.88M 0.1%
344,146
+4,300
+1% +$47.3K
PHAS
110
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$3.45M 0.09%
2,613,825
+32,526
+1% +$52.7K
OKUR
111
OnKure Therapeutics
OKUR
$164M
$3.36M 0.08%
114,319
– –
VIGL
112
DELISTED
Vigil Neuroscience
VIGL
$3.32M 0.08%
+471,958
New +$6.23M
CLDX icon
113
Celldex Therapeutics
CLDX
$3.37B
$3.31M 0.08%
+97,317
New +$3.11M
SPRB
114
Spruce Biosciences
SPRB
$127M
$3.26M 0.08%
21,636
– –
VINC
115
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3.26M 0.08%
40,710
+250
+0.6% +$30.9K
EPIX
116
DELISTED
ESSA Pharma
EPIX
$3.24M 0.08%
524,944
+13,900
+3% +$122K
BLSA
117
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.05M 0.08%
309,000
– –
TPST icon
118
Tempest Therapeutics
TPST
$16.6M
$2.78M 0.07%
63,358
– –
FSTX
119
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$2.67M 0.07%
751,889
– –
PRLD icon
120
Prelude Therapeutics
PRLD
$385M
$2.55M 0.06%
368,959
– –
JYAC
121
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.03M 0.05%
206,200
– –
TLPH icon
122
Talphera
TLPH
$73.2M
$1.81M 0.05%
316,460
+165
+0.1% +$1.4K
ELVN icon
123
Enliven Therapeutics
ELVN
$4.35B
$1.58M 0.04%
210,601
+25
+0% +$165
APLT
124
DELISTED
Applied Therapeutics
APLT
$1.48M 0.04%
701,680
– –
BCEL
125
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.47M 0.04%
462,530
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rock Springs Capital Management held 140 positions worth $3.97B, down 8.2% from $4.33B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rock Springs Capital Management's Q1 2022 filing shows 5 new, 76 increased, 8 reduced and 5 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M. The largest sale was HCA Healthcare, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2022 buy was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M.
  • Rock Springs Capital Management added most to DexCom in Q1 2022, an estimated $20.7M increase.
  • Rock Springs Capital Management's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $18.8M.
  • Rock Springs Capital Management fully exited Immuneering in Q1 2022, selling an estimated $17.6M.
  • Rock Springs Capital Management's ten largest holdings make up 31% of its $3.97B portfolio in Q1 2022.
  • Rock Springs Capital Management opened 5 new positions and closed 5 in Q1 2022.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $3.97B.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.